11th Annual:
Latest Advancements and Data in Immuno-Oncology
Hear directly from science and business stakeholders on the latest data impacting IO to fight a wider range of cancers.
.jpg)
IO360° Delivers 4 Key Benefits
1. Delivering a 360° IO Community to Network and Form Collaborations
Build faster and more impactful collaborations with researchers, clinicians, biopharma leaders, investors and policymakers to advance cancer treatments
2. The Latest Data Driving Broader Impact
Hear directly from KOLs on the latest data to help advance and improve outcomes for more patients across a wider range of cancers
3. 360° Future-Focused Agenda
Stay ahead of the curve through 100+ multi-dimensional talks covering preclinical research, translational science, clinical development, operational strategies, cell therapy and business advancements
4. 10+ Hours of Networking Opportunities
Meet with key stakeholders in biopharma, academia, investors and regulatory through 1:1 meetings and scheduled functions
2025 Key Topics
Biomarkers/Assay Development
Business and Investing Aspects
Discovery/Preclinical
Autoimmune Disease & IO
ADCs & IO
IO Combinations
Translational Science
Imaging Advancements
Cell Therapy
Clinical Operations
Clinical Developments
Neoadjuvant/Adjuvant Therapy
New Tech in Transformational Biology
And More
2025 Keynote & VIP All-Star Line Up
First FDA- Approved TCR Therapy for Solid Tumors
Dr Elliot Norry
Adaptimmune
Evolution and Future Directions in Cell Therapy
Dr Crystal Mackall
Stanford University
Investments & Adopting to IO Market Dynamics
Dr Arie Belldegrun
Allogene
CAR-T in Autoimmune Diseases
Dr Georg Schett
FAU Erlangen-Nürnberg
Designing Best-in-Class ADCs in IO
Dr Deepa Pakianathan
Delphi Ventures / Stealth Oncology Company
Strategic Innovations & Industry Trends
Dr Andrew Baum
Pfizer
Translational Science & Clinical Development Trailblazers
.jpeg)
Dr Jonathan Rosenberg
MSKCC
.jpeg)
Dr Alexander Eggermont
Princess Máxima Center for Pediatric Oncology
Dr Nina Shah
AstraZeneca
.jpg)
Dr Charles Drake
J&J Innovative Medicine
.jpeg)
Dr Delfi Krishna
Immatics Biotechnologies
.jpeg)
Dr Olivier Rixe
Daiichi Sankyo
.png)
Dr Johanna Bennell
Roche
.jpeg)
Dr Gregory Sawyer
Moffitt Cancer Center
.jpg)
Dr Naiyer Rizvi
Synthekine
.jpeg)
Dr Rosanna Ricafort
BMS
Transformational Biology Experts
.jpg)
Dr William Hawkins
MUSC Hollings Cancer Center
.jpg)
Dr Dushen Chetty
Novartis
Dr Raluca Verona
AbbVie
.jpg)
Dr Kazusa Ishii
NCI
Investment and Business Development Pioneers
.png)
Rajiv Kaul
Fidelity Investments
.jpg)
Rakhshita Dhar
Leaps by Bayer
.png)
Dr Carl Gordon
OrbiMed Advisors, LLC
Kallie Dirks
Morgan Stanley
.jpg)
Dr Emmett Schmidt
Merck
Innovators in IO Biotech
.png)
Dr Birgit Schultes
Intellia Therapeutics
Dr Priti Hegde
Kite Pharma
Dr Theresa LaVallee
Coherus BioSciences
Dr Roy Baynes
Eikon Therapeutics
Dr Ruben Rodriguez
cTRL Therapeutics
Clinical Operations Leadership
.jpg)
Andy Lee
Merck
.jpg)
Sarah White
Brigham and Women’s Hospital
.jpg)
Marta Arias-Salgado
Merck
Dr Michael Ku
Pfizer
.jpg)
Luisa Freitas Dos Santos
GSK
Key Issues and Challenges the 2025 Meeting Will Address
A message from founding Advisor, Axel Hoos, MD, PhD, former CEO of Scorpion Therapeutics
Networking and Business Opportunities
Partnering/One-on-One Meetings:
• Dedicated partnering tables to connect with fellow industry professionals, investors and KOLs
• Partnering tool to schedule partnering meetings
• Meeting times occur throughout all breaks, lunches and receptions
• Set up multiple meetings per day
• Search other attendee profiles
• Send private message to other attendees
• Dedicated partnering help desk
Scheduled Networking:
IO360° networking opportunities take place throughout the entire event including:
• Scheduled morning and afternoon breaks
• Lunches
• Reception
• Access to the Exhibit hall
• Early evening organized historical walks
2025 Event Features
.png)
.png)
.png)
Who Attends
.png)
Companies Attending:
• AbbVie
• Abingworth
• Amgen
• Astellas Pharma
• AstraZeneca
• Avidity Partners
• Bayer Oncology
• BioNTech
• BMS
• Boehringer Ingelheim
• City of Hope
• Daichii-Sankyo
• Fred Hutchinson Cancer Center
• Invus Group
• Janssen
• Kite Pharma
• Memorial Sloan Kettering Cancer Center
• Merck
• Moderna
• Morgan Stanley
• Mount Sinai
• MPM BioImpact
• NCI
• Novartis
• OrbiMed
• RA Capital
• Regeneron
• Stanford University
• Stifel
• Takeda
• And More!
"By bringing together groups such as scientists, investors, and experts in clinical trial design and logistics, it creates a forum where there's quite a lot of folks participating who are not traditionally talking to one another on a daily basis." - Dr Roy Baynes, Eikon Therapeutics
Dr Kristen Hege Looks Back at Lessons Learned from a Career in CAR-T Therapy
Taking Lessons from the Last Decade of IO to Develop the Next Wave of Therapeutics
Dr Roy Baynes on Strategy Development for Keytruda
2025 Sponsors
